ASX:CTE

Cryosite Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume418 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Cryosite (ASX:CTE) Vs. BUX, IME, BD1, CRL, DVL, and EPGNY

Should you be buying CTE stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Cryosite, including (BUX) (BUX), 12144 (IME), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), dorsaVi (DVL), and Epigenomics (EPGNY).

Cryosite (ASX:CTE) and (BUX) (CNSX:BUX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cryosite and (BUX), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryosite0000N/A
(BUX)0000N/A

Profitability

This table compares Cryosite and (BUX)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CryositeN/AN/AN/A
(BUX)N/AN/AN/A

Earnings & Valuation

This table compares Cryosite and (BUX)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryosite$9.71 million0.00$515,455.60A$0.01N/A
(BUX)N/AN/AN/AN/AN/A

Cryosite has higher revenue and earnings than (BUX).

Summary

Cryosite beats (BUX) on 1 of the 1 factors compared between the two stocks.

Cryosite (ASX:CTE) and 12144 (CNSX:IME) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings for Cryosite and 12144, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryosite0000N/A
121440000N/A

Profitability

This table compares Cryosite and 12144's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CryositeN/AN/AN/A
12144N/AN/AN/A

Earnings & Valuation

This table compares Cryosite and 12144's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryosite$9.71 million0.00C$515,455.60A$0.01N/A
12144N/AN/AN/AN/AN/A

Cryosite has higher revenue and earnings than 12144.

Summary

Cryosite beats 12144 on 1 of the 1 factors compared between the two stocks.

Cryosite (ASX:CTE) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Profitability

This table compares Cryosite and BARD1 Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CryositeN/AN/AN/A
BARD1 Life SciencesN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Cryosite and BARD1 Life Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryosite0000N/A
BARD1 Life Sciences0000N/A

Earnings & Valuation

This table compares Cryosite and BARD1 Life Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryosite$9.71 million0.00$515,455.60A$0.01N/A
BARD1 Life Sciences$612,251.000.00$-6,644,706.43A($0.08)N/A

Cryosite has higher revenue and earnings than BARD1 Life Sciences.

Summary

Cryosite beats BARD1 Life Sciences on 3 of the 3 factors compared between the two stocks.

Cryosite (ASX:CTE) and Charles River Laboratories International (CNSX:CRL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Cryosite and Charles River Laboratories International's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryosite$9.71 million0.00$515,455.60A$0.01N/A
Charles River Laboratories InternationalN/AN/AN/AN/AN/A

Cryosite has higher revenue and earnings than Charles River Laboratories International.

Profitability

This table compares Cryosite and Charles River Laboratories International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CryositeN/AN/AN/A
Charles River Laboratories InternationalN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Cryosite and Charles River Laboratories International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryosite0000N/A
Charles River Laboratories International0000N/A

Summary

Cryosite beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

dorsaVi (ASX:DVL) and Cryosite (ASX:CTE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Earnings & Valuation

This table compares dorsaVi and Cryosite's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
dorsaVi$1.65 million0.00$-3,158,396.93A($0.01)N/A
Cryosite$9.71 million0.00$515,455.60A$0.01N/A

Cryosite has higher revenue and earnings than dorsaVi.

Profitability

This table compares dorsaVi and Cryosite's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
dorsaViN/AN/AN/A
CryositeN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for dorsaVi and Cryosite, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
dorsaVi0000N/A
Cryosite0000N/A

Summary

Cryosite beats dorsaVi on 3 of the 3 factors compared between the two stocks.

Cryosite (ASX:CTE) and Epigenomics (OTCMKTS:EPGNY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Cryosite and Epigenomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CryositeN/AN/AN/A
EpigenomicsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Cryosite and Epigenomics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryosite0000N/A
Epigenomics0000N/A

Earnings and Valuation

This table compares Cryosite and Epigenomics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryosite$9.71 million0.00$515,455.60A$0.01N/A
EpigenomicsN/AN/AN/AN/AN/A

Cryosite has higher revenue and earnings than Epigenomics.

Summary

Cryosite beats Epigenomics on 1 of the 1 factors compared between the two stocks.


Cryosite Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
BD1
BARD1 Life Sciences
0.5N/AN/A$0.00$612,251.000.00High Trading Volume
News Coverage
Gap Up
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
DVL
dorsaVi
0.5N/AN/A$0.00$1.65 million0.00High Trading Volume
Gap Up
Epigenomics logo
EPGNY
Epigenomics
0.6$13.77flat$0.00N/A0.00Increase in Short Interest
News Coverage
ETAH
Eternity Healthcare
0.6$0.00flat$0.00N/A0.00
GSS
Genetic Signatures
0.0N/AN/A$0.00$29.13 million0.00High Trading Volume
GTG
Genetic Technologies
0.0N/AN/A$0.00$25,714.000.00High Trading Volume
IBX
Imagion Biosystems
0.6N/AN/A$0.00$2.70 million0.00High Trading Volume
Gap Up
IDX
Integral Diagnostics
0.8N/AN/A$0.00$314.82 million0.00High Trading Volume
News Coverage
Gap Up
LSH
Lifespot Health
0.5N/AN/A$0.00$22,127.000.00High Trading Volume
Gap Up
MEDD
Medical Imaging
0.4$0.01flat$0.00N/A0.00Gap Down
OSL
OncoSil Medical
0.5N/AN/A$0.00$2.22 million0.00High Trading Volume
Gap Up
PRLX
Parallax Health Sciences
0.5$0.02flat$0.00N/A0.00
RHY
Rhythm Biosciences
0.0N/AN/A$0.00$1.21 million0.00High Trading Volume
Sartorius Aktiengesellschaft logo
SRT3
Sartorius Aktiengesellschaft
0.6$450.60flat$0.00N/A0.00High Trading Volume
Siemens Healthineers logo
SMMNY
Siemens Healthineers
0.5$27.90flat$0.00N/A0.00Decrease in Short Interest
News Coverage
SIL
Smiles Inclusive
0.4N/AN/A$0.00$36.48 million0.00High Trading Volume
Gap Up
VHT
Volpara Health Technologies
0.5N/AN/A$0.00$15.22 million0.00High Trading Volume
Gap Up
OBJ
Wellfully Limited (OBJ.AX)
0.0N/AN/A$0.00$1.48 million0.00High Trading Volume
WUXIF
WuXi AppTec
1.0$19.88flat$0.00N/A0.00Decrease in Short Interest
Gap Down
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.